thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
This and other research indicate that the endocannabinoid system and TRPV1 may play an important role in the analgesic effect of paracetamol. In 2018, Suemaru et al. found that, in mice, paracetamol exerts an anticonvulsant effect by activation of the TRPV1 receptors and a decrease in neuronal excitability by hyperpolarization of neurons. The exact mechanism of the anticonvulsant effect of paracetamol is not clear. According to Suemaru et al., acetaminophen and its active metabolite AM404 show a dose-dependent anticonvulsant activity against pentylenetetrazol-induced seizures in mice. In 2025, Maatuf et al. reported that AM404 is also produced by peripheral sensory neurons in vitro and blocks the action of pain-sensing Nav1.8 and 1.7 channels at nanomolar concentrations. AM404 injected into the hind paw of rats increases the pain threshold for the treated paw, but not the untreated paw, confirming the peripheral nature of this effect. It also lowers pain responses in a few other in vivo models when injected directly into the affected area. Other tested metabolites of paracetamol do not block pain-sensing sodium channels in vitro.
At 8:32 a.m., FAA officials were notified Flight 11 had been hijacked, and they notified the North American Aerospace Defense Command (NORAD). NORAD scrambled two F-15s from Otis Air National Guard Base in Massachusetts; they were airborne by 8:53 a.m. Because of slow and confused communication from FAA officials, NORAD had nine minutes' notice, and no notice about any of the other flights before they crashed. After both of the Twin Towers had been hit, more fighters were scrambled from Langley Air Force Base in Virginia at 9:30 a.m. At 10:20 am, Vice President Dick Cheney issued orders to shoot down any commercial aircraft that could be positively identified as being hijacked. These instructions were not relayed in time for the fighters to take action. Some fighters took to the air without live ammunition, knowing that to prevent the hijackers from striking their intended targets, the pilots might have to intercept and crash their fighters into the hijacked planes, possibly ejecting at the last moment. For the first time in U.S. history, the emergency preparedness plan Security Control of Air Traffic and Air Navigation Aids (SCATANA) was invoked, stranding tens of thousands of passengers across the world. Ben Sliney, in his first day as the National Operations Manager of the FAA, ordered that American airspace be closed to all international flights, causing about 500 flights to be turned back or redirected to other countries.
Syngenta's azoxystrobin was the first product launched. BASF's F-500 Series, which includespyraclostrobin and kresoxim-methyl, and Bayer CropScience, and Monsanto are developing new compounds in this class. Combination pesticides, such as Monsanto's Genuity and SmartStax are more and more frequently used.
==== United Kingdom ==== On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-HO-PCP.
Butonitazene is a benzimidazole derivative with opioid effects, which has been sold over the internet as a designer drug. It has relatively low potency compared to many related compounds, and has generally been encountered as a component of mixtures with other substances rather than in its pure form. However, it is still several times the potency of morphine and has been implicated in several cases of drug overdose. Butonitazene is a Schedule I drug in the US, along with several related compounds.
Sources: en.wikipedia.org
=== Basicity expressed as dissociation constant of conjugate acid === Because the relationship pKb = pKw − pKa holds only in aqueous solutions (though analogous relationships apply for other amphoteric solvents), subdisciplines of chemistry like organic chemistry that usually deal with nonaqueous solutions generally do not use pKb as a measure of basicity. Instead, the pKa of the conjugate acid, denoted by pKaH, is quoted when basicity needs to be quantified. For base B and its conjugate acid BH+ in equilibrium, this is defined as
=== South America === There are outlets in Brazil in the São Paulo area, Campinas, Rio de Janeiro and Brasília. Taco Bell has stores in Chile, which many of them are operated in conjunction (and in the same facilities) with Pizza Hut. All Taco Bell stores are in shopping malls located mainly in Santiago. Peru has branches in Lima. There were four outlets in the Bogotá area in Colombia, but these closed in late 2018. Taco Bell operated in Ecuador between 1993 and 2009, it returned to operate on October 7, 2025, in Quito.
== Species distribution == Across vertebrates, four paralogous TCAPs (TCAP-1–4) exhibit structural similarity to corticotropin-releasing hormone (CRH) and other secretin-family peptides and have been shown in rodent and non-mammalian models to exert anxiolytic-like effects, modulate glucose and energy homeostasis, and participate in broader tissue-specific signaling, highlighting TCAPs as evolutionarily conserved peptides.
Prior to 1919 only atomic weights averaged over a very large number of atoms was available. In that year, Francis Aston built the first mass spectrograph, an improved form of a device built by J. J. Thomson to measure the deflection of positively charged atoms by electric and magnetic fields. Aston was then able to separate the isotopes of many light elements including neon, 20Ne and 22Ne. Aston discovered the isotopes matched William Prout's whole number rule: the mass of every isotope is a whole number multiple of hydrogen. Significantly, the one exception to this whole number rule was hydrogen itself, which had a mass value of 1.008. The excess mass was small, but well outside the limits of experimental uncertainty. Aston and others realized this difference was due to the binding energy of atoms. When a number of hydrogen atoms are bound into an atom, that atom's energy must be less than the sum of the energies of the separate hydrogen atoms. That lost energy, according to the mass-energy equivalence principle, means the atomic mass will be slightly less than the sum of the masses of its components. Aston's work on isotopes won him the 1922 Nobel Prize in Chemistry for the discovery of isotopes in a large number of non-radioactive elements, and for his enunciation of the whole number rule.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.